Cancer research

Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study

Retrieved on: 
Wednesday, April 5, 2023
University, Biotechnology, Education, Health, Pharmaceutical, Oncology, Health Technology, Research, Surgery, Genetics, Science, University College London, Francis Crick Institute, DNA, CT, UCL, Cancer research, Cancer, Lung cancer, Cancer Research UK, NSCLC, Doctor of Philosophy, PSNL, MRD, Patient, Medicine, Neoplasm, Recurrence, Dentistry, Medical imaging, Chief Justice of Hungary, MD

Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy NeXT Personal , a personalized liquid biopsy-based research assay, for the TRACERx study, a groundbreaking lung cancer initiative funded by Cancer Research UK.

Key Points: 
  • Personalis, Inc. (Nasdaq: PSNL), Cancer Research UK’s Cancer Research Horizons, University College London (UCL), and the Francis Crick Institute today announced a collaboration to deploy NeXT Personal , a personalized liquid biopsy-based research assay, for the TRACERx study, a groundbreaking lung cancer initiative funded by Cancer Research UK.
  • Previously reported findings from the TRACERx study have transformed our understanding of the evolution of the most common type of lung cancer, non-small cell lung cancer (NSCLC), and the TRACERx research team is taking practical steps to make precision medicine for lung cancer patients a reality.
  • The study will utilize Personalis’ NeXT Personal assay, which has demonstrated high sensitivity for detecting a key marker – circulating tumor DNA (ctDNA) – from a patient’s blood sample, with the goal of enabling earlier detection of residual or recurrent cancer.
  • Our high sensitivity NeXT Personal MRD assay is uniquely poised to support the study by providing insights about how tumor biology changes over time and by enabling earlier detection of MRD and cancer recurrence.

Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

Retrieved on: 
Thursday, March 23, 2023
AACR, Mayo Clinic, University, Education, Cancer research, American Society of Clinical Oncology, GSK-3, United States Air Force Scientific Advisory Board, MD Anderson Cancer Center, Doctor of Philosophy, CRUK, NAC, ASCO, Organization, DO, Food and Drug Administration Amendments Act of 2007, Patient, Clinical professor, American Association for Cancer Research, FDA, Therapy, Society, Food, Pharmaceutical industry, Actuate

CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.
  • “We congratulate Dr. LoRusso for being elected to lead the AACR and for her significant contributions to the field of cancer research and therapeutic development,” said Daniel M. Schmitt, President & CEO of Actuate.
  • “As a founding member of Actuate’s Scientific Advisory Board, Dr. LoRusso has played an invaluable role in designing the innovative accelerated clinical development plans for elraglusib, Actuate’s best-in-class agent, for the benefit of adult and pediatric patients with difficult-to-treat cancers.”
    Dr. LoRusso joined the Actuate Scientific Advisory Board in October 2015.
  • She also has worked closely with Cancer Research United Kingdom (CRUK), as the chair of their New Agents Committee (NAC).

Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

Retrieved on: 
Thursday, March 23, 2023
AACR, Mayo Clinic, University, Education, Cancer research, American Society of Clinical Oncology, GSK-3, United States Air Force Scientific Advisory Board, MD Anderson Cancer Center, Doctor of Philosophy, CRUK, NAC, ASCO, Organization, DO, Food and Drug Administration Amendments Act of 2007, Patient, Clinical professor, American Association for Cancer Research, FDA, Therapy, Society, Food, Pharmaceutical industry, Actuate

CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.

Key Points: 
  • CHICAGO and FORT WORTH, Texas, March 23, 2023 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.
  • “We congratulate Dr. Russo for being elected to lead the AACR and for her significant contributions to the field of cancer research and therapeutic development” said Daniel M. Schmitt, President & CEO of Actuate.
  • Dr. LoRusso has served in leadership positions of several other organizations, including the education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop.
  • She also has worked closely with Cancer Research United Kingdom (CRUK), as the chair of their New Agents Committee (NAC).

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs

Retrieved on: 
Friday, March 17, 2023
Oncology, Partnership, Probability, Cancer research, Cancer, Cancer Research UK, Intelligence, Research, CRUK, Patient, Drug discovery, Neoplasm, Pharmaceutical industry, Glutaminase

EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.

Key Points: 
  • EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world’s largest private funder of cancer research, Cancer Research UK (CRUK), today announce that they have partnered to drive the development of oncology drugs utilizing Predictive Oncology’s PEDAL™ platform.
  • “Our collaboration with Cancer Research Horizons represents a fundamental shift in drug discovery that could lead to the accelerated development of cancer therapies using compounds originating from the CRUK network and developed by Cancer Research Horizons in partnership with their global network,” said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology.
  • We look forward to applying Predictive Oncology’s expertise, enabling technology and dedication to progress exciting cancer therapeutics,” explained Tony Hickson, Chief Business Officer for Cancer Research UK and Cancer Research Horizons.
  • Cancer Research Horizons realizes cancer patient benefit from not-for-profit research and works closely with leading cancer scientists, institutes and companies to protect, develop and commercialize oncology-related discoveries.

Ellipses Pharma: EP0042 Receives Orphan Drug Designation from the US Food and Drug Administration

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Health, FDA, Research, Science, Pharmaceutical, Biotechnology, Aurora, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Drug development, The Institute, AML, Ellipses, Cancer research, Breast Cancer Now, Risk, ASH, FLT3, Rare, Patient, ODD, Breast cancer, Food, Safety, Institute of Cancer Research, Drug discovery, IND, Acute leukemia, Pharmaceutical industry

Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia (AML).

Key Points: 
  • Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia (AML).
  • In February 2023, the FDA approved EP0042’s Investigational New Drug Application, which allowed for the opening of additional trial sites in the US for this compound.
  • EP0042 is being developed as a new potential treatment to combat acquired resistance to FLT3 inhibitors in patients with AML.
  • The designation is an important milestone in the development of EP0042, and underscores the work we are already undertaking towards accelerating its potential access to patients.

Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia

Retrieved on: 
Wednesday, February 1, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Aurora, Breast Cancer Now, AML, Drug development, Institute of Cancer Research, Safety, ASH, Patient, Clinical trial, Cancer research, Food, FLT3, Risk, Investigational New Drug, FLT-3, Society, The Institute, Drug discovery, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breast cancer, IND, Pharmaceutical industry, Ellipses

Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042, a dual FLT-3 and Aurora kinase inhibitor.

Key Points: 
  • Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for EP0042, a dual FLT-3 and Aurora kinase inhibitor.
  • EP0042 is being developed as a new potential treatment to combat acquired resistance to FLT3 inhibitors in patients with AML.
  • Once a recommended Phase 2 dose is confirmed, Ellipses will continue to evaluate EP0042 as a monotherapy and explore EP0042 in combination with established standard treatments.
  • This will help us in achieving our strategic goal of bringing potential new treatment options to patients in need at unprecedented speed, whilst also allowing us to engage with key industry and academic partners.

Worldwide Cancer Immunotherapy Industry to 2033 - Featuring Novartis, Pfizer, AstraZeneca and Genentech Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, January 30, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, DNA, Stanford University, Immunotherapy, Merck & Co., BioNTech, Incidence, Endometrial cancer, Cancer research, USD, Partnership, Growth, FDA, US, Pharmaceutical industry

Additionally, rise in funds for the development of innovative therapies and various strategic measures implemented by top companies is supporting the market growth.

Key Points: 
  • Additionally, rise in funds for the development of innovative therapies and various strategic measures implemented by top companies is supporting the market growth.
  • However, immunotherapy adverse effects are expected to hinder the growth.
  • Rise in funds for the development of innovative therapies is expected to propel the market growth during the projected period.
  • For instance, the U.S. National Cancer Institute and Cancer Research UK's Cancer Grand Challenges project provided USD 13 million in funding to a team of Stanford scientists in June 2022.

Global 3D Cell Culture Market Predicted to Observe Significant Growth by 2031, due to the Versatile Properties such as High Strength and Low Price of 3D Cell Culture | [200-Pages] Analysis by Research Dive

Retrieved on: 
Monday, February 13, 2023
End user, Organization, Cancer, Biotechnology, Vaccine, Coronavirus, Government, Regenerative medicine, Scaffolding, Skin cancer, University, Hydrogel, Midsayap Diagnostic Center and Hospital, Finnish Cultural and Academic Institutes, Diagnosis, Drug development, Stem cell, Cancer research, Research, Cell culture, Lung cancer, Growth, Prevalence, 3D, Advantage Business Media, Video game, Fine chemical, Hospital

NEW YORK, Feb. 13, 2023 /PRNewswire/ --Research Dive has added a new report to its offering titled, "3D Cell Culture Market Product (Scaffold Based 3D Cell Culture, Scaffold Free 3D cell culture, and Microfluidic Organ-on-a-chip Models), Application (Cancer Research, Stem Cell Research, Drug Discovery & Development, and Regenerative Medicine), End User (Biotechnology and Pharmaceutical Companies, Contract Research Laboratories, Hospitals, Diagnostic Centers, and Academic Institutes): Global Opportunity Analysis and Industry Forecast, 2022-2031". 

Key Points: 
  • The global 3D cell culture market is expected to witness prominent growth during the forecast period, owing to the increasing awareness of oncological diseases worldwide.
  • According to the report, the global 3D cell culture market is anticipated to generate a revenue of $5,656.7 million and grow at a CAGR of 15.07% during the analysis timeframe from 2022 to 2031.
  • Though the rise of the novel coronavirus has devastated several other industries, it has had a positive impact on the 3D cell culture market.
  • By region, the North America region of the 3D cell culture market is predicted to have enormous growth opportunities throughout the estimated timeframe.

Insights on Global Cancer Vaccines Market Size & Share Projected to Hit at USD 19.27 Billion and Rise at a CAGR of 14.75% By 2030: Industry Trends, Demand, Value, Analysis & Forecast Report | Facts and Factors

Retrieved on: 
Tuesday, February 7, 2023
National Center for Immunization and Respiratory Diseases, Prostate, Brain, Vaccine, Spinal cord, Woman, Smoking, Government, Hospital, Blood, White blood cell, Cancer, Breast, HPV, Rectum, Leukemia, Immunity, Projection, Tissue, Lymphoma, Radiation, Bone marrow, Lung, Patient, Cancer research, Skin, Bladder cancer, Prostate cancer, Partner (business rank), CNS, Cartilage, Risk, USD, Immune system, Carcinoma, Lung cancer, Vulvar cancer, Central nervous system, Cervical cancer, Classification, Medical imaging, Pharmaceutical industry

The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.

Key Points: 
  • The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.
  • Based on indication, the global market is divided into bladder cancer, cervical cancer, lung cancer, prostate cancer, and others.
  • List of Key Players in Cancer Vaccines Market:
    Key questions answered in this report:
    What are the growth rate forecast and market size for CANCER VACCINES Market?
  • How can I receive a free copy of the CANCER VACCINES Market sample report and company profiles?

Insights on Global Cancer Vaccines Market Size & Share Projected to Hit at USD 19.27 Billion and Rise at a CAGR of 14.75% By 2030: Industry Trends, Demand, Value, Analysis & Forecast Report | Facts and Factors

Retrieved on: 
Tuesday, February 7, 2023
National Center for Immunization and Respiratory Diseases, Prostate, Brain, Vaccine, Spinal cord, Woman, Smoking, Government, Hospital, Blood, White blood cell, Cancer, Breast, HPV, Rectum, Leukemia, Immunity, Projection, Tissue, Lymphoma, Radiation, Bone marrow, Lung, Patient, Cancer research, Skin, Bladder cancer, Prostate cancer, Partner (business rank), CNS, Cartilage, Risk, USD, Immune system, Carcinoma, Lung cancer, Vulvar cancer, Central nervous system, Cervical cancer, Classification, Medical imaging, Pharmaceutical industry

The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.

Key Points: 
  • The global cancer vaccines market is projected to grow due to the increasing number of types of cancer and the population suffering from such cancers.
  • Based on indication, the global market is divided into bladder cancer, cervical cancer, lung cancer, prostate cancer, and others.
  • List of Key Players in Cancer Vaccines Market:
    Key questions answered in this report:
    What are the growth rate forecast and market size for CANCER VACCINES Market?
  • How can I receive a free copy of the CANCER VACCINES Market sample report and company profiles?